Shares of Xencor Inc. (NASDAQ:XNCR) rose 2.6% on Friday . The stock traded as high as $21.76 and last traded at $21.41, with a volume of 87,188 shares trading hands. The stock had previously closed at $20.86.

XNCR has been the subject of several recent research reports. Wedbush restated an “outperform” rating and issued a $27.00 price objective on shares of Xencor in a report on Tuesday, June 28th. Zacks Investment Research upgraded shares of Xencor from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a report on Tuesday, July 5th. Canaccord Genuity reiterated a “buy” rating on shares of Xencor in a report on Tuesday, May 3rd. Leerink Swann reiterated an “outperform” rating and issued a $18.00 target price on shares of Xencor in a report on Wednesday, June 29th. Finally, Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Xencor in a report on Monday, May 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $22.33.

The company has a market cap of $879.17 million and a PE ratio of 22.82. The stock’s 50-day moving average is $20.09 and its 200-day moving average is $15.01.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.13 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $1.31. The business had revenue of $66 million for the quarter, compared to analysts’ expectations of $7.43 million. Analysts forecast that Xencor Inc. will post $0.72 EPS for the current year.

In other news, VP John J. Kuch sold 25,000 shares of the stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $21.95, for a total transaction of $548,750.00. Following the completion of the transaction, the vice president now directly owns 92,078 shares in the company, valued at approximately $2,021,112.10. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder John S. Stafford III sold 96,828 shares of the stock in a transaction on Tuesday, August 23rd. The stock was sold at an average price of $21.73, for a total value of $2,104,072.44. The disclosure for this sale can be found here.

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.